Transition Therapeutics Inc (TTH.TO) People | Reuters.com
Edition:
United States

Transition Therapeutics Inc (TTH.TO)

TTH.TO on Toronto Stock Exchange

0.98CAD
21 Jun 2016
Change (% chg)

-- (--)
Prev Close
$0.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,873
52-wk High
$3.87
52-wk Low
$0.94

Summary

Name Age Since Current Position

Tony Cruz

1999 Chairman of the Board, Chief Executive Officer

Carl Damiani

40 2015 President, Chief Operating Officer

Nicole Rusaw

39 2011 Chief Financial Officer

Bruce Connop

43 2012 Vice President - Non-Clinical & Pharmaceutical Development

Aleksandra Pastrak

46 2011 Vice President - Clinical Development and Medical Officer

Louis Alexopoulos

1998 Secretary

Michael Ashton

69 2012 Lead Independent Director

Paul Baehr

69 2002 Independent Director

Christopher Henley

52 2000 Independent Director

Gary Pace

67 2012 Independent Director

Biographies

Name Description

Tony Cruz

Dr. Tony Cruz is Chairman of the Board, Chief Executive Officer of Transition Therapeutics Inc. Dr. Cruz is one of the founders of Transition Therapeutics and has held the position of Chief Executive Officer of Transition Therapeutics since its inception in July 1998. Dr. Cruz was a Co-Founder, Vice-President and Director at Angiotech Pharmaceuticals Inc. Dr. Cruz has been a Senior Scientist at Mount Sinai Hospital since 1995 and was the CEO and President of the Canadian Arthritis Network until 2001. He has also served as a consultant for biotechnology companies and investment firms.

Carl Damiani

Mr. Carl Damiani is President, Chief Operating Officer of the Company. He was Vice President - Business Development of Transition Therapeutics Inc. Mr. Damiani is a key member of the Company's management team and is responsible for a broad range of activities, including licensing and intellectual property strategies. Prior to joining Transition, Mr. Damiani led multiple successful start-up businesses in the biotech and services industries.

Nicole Rusaw

Ms. Nicole Rusaw, C.A., is Chief Financial Officer of Transition Therapeutics Inc. Ms. Rusaw has been with the Company since 2005 and was appointed as Chief Financial Officer in December 2011. While at Transition, Ms. Rusaw has been responsible for a broad range of activities with a focus on financial reporting and regulatory compliance as well as involvement in various equity financings and strategic acquisitions.

Bruce Connop

Dr. Bruce Connop is Vice President - Non-Clinical & Pharmaceutical Development of Transition Therapeutics Inc. Dr. Connop has been with Transition since 2006 and served as Sr. Director, Nonclinical Drug Development until he was appointed VP, Non-Clinical & Pharmaceutical Development in 2012. With his expertise in pharmacology, toxicology and manufacturing he is responsible for a broad range of activities and has made significant contributions to the advancement of pipeline products. Dr. Connop holds a Ph.D. from Queen’s University and has had experience at other biotech and pharmaceutical companies.

Aleksandra Pastrak

Dr. Aleksandra Pastrak is Vice President - Clinical Development and Medical Officer of Transition Therapeutics Inc. Dr. Pastrak has been with Transition since 1999 and served as VP, Research since 2005 until she was appointed VP, Clinical Development in 2011. With her expertise in medicine and pharmacology, she has made an invaluable contribution to the development of our clinical programs for various therapeutic products. Dr. Pastrak holds an MD from the School of Medicine at the University of Belgrade and M.Sc. and Ph.D. degrees in Clinical Pharmacology from the University of Toronto.

Louis Alexopoulos

Mr. Louis Alexopoulos is Secretary of Transition Therapeutics Inc. Mr. Alexopoulos is a Barrister and Solicitor and Partner at the law firm Sotos Associates.

Michael Ashton

Mr. Michael Richard Dwyer Ashton is Lead Independent Director of Transition Therapeutics Inc. Mr. Ashton has been an independent consultant to the pharmaceutical industry since March 2006. Prior thereto, he was the Chief Executive Officer of SkyePharma PLC. He has 30 years of experience in the Pharmaceutical industry having worked for Merck, Pfizer, Purepac and Faulding, where Mr. Ashton was Chairman, President and CEO. Mr. Ashton currently sits on boards of directors of the following public companies; Hikma Pharmaceuticals PLC, and Proximagen Neuroscience PLC.

Paul Baehr

Mr. Paul Baehr is Independent Director of Transition Therapeutics Inc. Mr. Baehr is President, Chief Executive Officer and Chairman, IBEX Technologies. Previously Executive Vice President, Sterling, Winthrop Pharmaceutical Division, New York, NY; Senior Vice President, CIBA-GEIGY Pharmaceuticals, Summit, NJ.

Christopher Henley

Mr. Christopher Henley is Independent Director of Transition Therapeutics Inc. Mr. Henley is founder and President of Henley Capital Corporation, a boutique investment dealer specializing in financial, mergers and acquisitions and advisory services to companies covering the full spectrum of high technology. Prior to this, Mr. Henley was the head of investment banking in Toronto and ran the High Technology and Communications practice at Canada's largest independent employee-owned investment dealer. He has been an investment banker for over 20 years and sits on a number of public and private boards of directors.

Gary Pace

Dr. Gary W. Pace, Ph.D., is Independent Director of Transition Therapeutics Inc. He is Chairman and founder of the recently formed Sova Pharmaceuticals Inc. He is also founder and director and former Chairman and CEO of QRxPharma Ltd. (ASX:QRX), a development stage bio-pharmaceutical company and a Director of ResMed Inc (NYSE:RMD). Dr. Pace holds a B.Sc. with honors from the University of New South Wales (Australia), a PhD from MIT is a Fellow of the Australian Academy of Technological Sciences and Engineering.

Basic Compensation

Options Compensation